STAT+: Wyden wants details on Merck’s U.S. taxes as part of expanding probe into pharma practices

Sen. Ron Wyden wants details on Merck's U.S. taxes as part of an expanding probe into pharma tax practices.

The head of the U.S. Senate Finance Committee is seeking details from Merck about the taxes paid during a recent three-year period as part of an ongoing investigation into tax practices by multinational pharmaceutical companies and efforts made to avoid paying U.S. taxes.

Earlier this year, Sen. Ron Wyden (D-Ore.), who chairs the committee, began probing Bristol Myers Squibb over a deal in which the company used offshore subsidiaries allegedly to avoid paying up to $1.4 billion in U.S. taxes on prescription drug sales. And he previously accused AbbVie of shifting profits offshore and registering patents in low-tax jurisdictions to avoid paying U.S. corporate income taxes.

Continue to STAT+ to read the full story…